For:
ads
Product Development
GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute

GigaGen is developing polyclonal antibodies for COVID-19 and other infectious diseases that could be more potent and easier to supply than convalescent plasma.  GigaGen Inc. plans to submit ...

BMS heeds BIO’s call to ‘walk the talk’

A week after BIO unveiled its BIOEquality initiative, BMS said it is preparing to invest $300 million to increase diversity in clinical trials of its therapies and the representation of Blacks and ...

Regulation
Aug. 12 Quick Takes: Approvals for DMD, acute pain; plus Priority Review for Fabry, hypercholesterolemia therapies and more  

FDA approves a second targeted DMD therapyNS Pharma Inc.’s Viltepso viltolarsen received accelerated approval from FDA to treat Duchenne muscular dystrophy in patients amenable to exon 53 ...

Deals
Ligand looking to future deals around protein expression platform with Pfenex takeout

Ligand is adding to its stable of drug discovery technologies to partner with biopharmas through its acquisition of Pfenex and its protein expression platform. The deal is the largest acquisition by ...

Operation Warp Speed commitments top $10B

Operation Warp Speed closed its sixth procurement deal Tuesday, pledging an additional $1.5 billion to Moderna for 100 million doses of its COVID-19 vaccine, mRNA-1273. The U.S. initiative has ...

Finance
Codon adds Roche Venture’s Mutz to team to capitalize therapeutic, synthetic bio start-ups

After seven years of making angel investments with founder and former CMEA Managing Director Karl Handelsman as its sole LP, San Francisco-based VC Codon Capital has brought Mitchell Mutz on board to ...

Management Tracks
NHC’s Boutin to head patient advocacy at Novartis; plus changes at Moderna, PIC, Atea, Terns, NBE and Omega

National Health Council CEO Marc Boutin has joined Novartis AG (NYSE:NVS; SIX:NOVN) as global head of patient engagement and advocacy. The NHC is  an umbrella group comprising more than 140 ...

BioCentury ISSN 1097-7201